- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient decision-making, revealing key treatment preferences and highlighting the importance of incorporating these insights into clinical practice when selecting BTK inhibitors for patients with CLL or SLL.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA).”
- What was the objective of the study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and how does it change your perspective as a clinician when deciding between BTKis for patients with CLL or SLL?
Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk R/R CLL
March 7th 2025Treatment with liso-cel induced long-term complete remission rates and high undetectable minimal residual disease rates in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma following progression on Bruton tyrosine kinase inhibition and venetoclax.
Read More
Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better
March 5th 2025Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.
Read More
Personalized CLL Therapy With MRD Guidance Improves Survival Outcomes
February 6th 2025A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.
Read More
